Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...
Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?
We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...
Medical Dialogues10h
Novo Nordisk reshapes Executive management team
Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...
Denmark Stocks Slide Into Bear Market as Tariffs, Novo Weigh
Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S weigh.
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
pharmaphorum16h
Lilly holds off on tirzepatide filing in obesity, waiting for second trial
Novo Nordisk's CagriSema data disappoints investors again Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline. R&D ...